Filings with the U.S. Securities Exchange Commission (SEC)
In accordance with SEC regulations, Genelabs and certain other persons file reports related to Genelabs that are available on the SEC's EDGAR online database. The EDGAR database includes the following filings on Genelabs: annual reports on form 10-K, quarterly reports on form 10-Q, current reports on form 8-K, proxy statements and “Section 16” reports by directors and executive officers on their holdings and transactions of Genelabs' stock. Click on the links below to see these documents.

Company SEC filings on EDGAR

Section 16 filings on EDGAR

Cautionary Language Regarding Forward-Looking Statements
Materials in this website may contain information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They may use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, research, clinical trials, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors will be important in determining our actual future results. Our actual results may vary materially, and there are no guarantees about the performance of Genelabs stock.

We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You should consult any further disclosures we make in our reports to the SEC. In particular, you should read the section entitled "Risk Factors" in our most recent 10-K report to the SEC, as it may be updated in our subsequent 10-Q and 8-K reports. Other factors besides those listed there could also adversely affect Genelabs.

© Genelabs Technologies, Inc. All rights reserved. - Terms of Use